Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.

Low, JG; Sung, C; Wijaya, L; Wei, Y; Rathore, AP; Watanabe, S; Tan, BH; Toh, L; Chua, LT; Hou, Y; +15 more... Chow, A; Howe, S; Chan, WK; Tan, KH; Chung, JS; Cherng, BP; Lye, DC; Tambayah, PA; Ng, LC; Connolly, J; Hibberd, ML; Leo, YS; Cheung, YB; Ooi, EE; Vasudevan, SG; (2014) Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. The Lancet infectious diseases, 14 (8). pp. 706-15. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(14)70730-3

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(14)70730-3

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar